keyword
MENU ▼
Read by QxMD icon Read
search

Lucentis

keyword
https://www.readbyqxmd.com/read/28654629/predictors-of-one-year-visual-outcomes-after-anti-vascular-endothelial-growth-factor-treatment-for-neovascular-age-related-macular-degeneration
#1
Laurent Kodjikian, Evelyne Decullier, Eric H Souied, Adeline Roux, Gilles Aulagner, Laure Huot
PURPOSE: To determine predictors of best-corrected visual acuity (BCVA) outcomes 1 year after ranibizumab or bevacizumab treatment for neovascular age-related macular degeneration, within the French Study Group Avastin versus Lucentis for neovascular age-related macular degeneration (GEFAL). METHODS: Patients aged ≥50 years presenting subfoveal neovascular age-related macular degeneration were randomized to receive ranibizumab or bevacizumab (3 monthly intravitreal injections followed by an as-needed regimen)...
June 20, 2017: Retina
https://www.readbyqxmd.com/read/28613352/comparison-of-ranibizumab-and-bevacizumab-for-macular-edema-secondary-to-retinal-vein-occlusions-in-routine-clinical-practice
#2
Mehnaz Khan, Karen M Wai, Fabiana Q Silva, Sunil Srivastava, Justis P Ehlers, Aleksandra Rachitskaya, Amy Babiuch, Ryan Deasy, Peter K Kaiser, Andrew P Schachat, Alex Yuan, Rishi P Singh
BACKGROUND AND OBJECTIVE: To determine outcomes of intravitreal ranibizumab (IVR) (Lucentis; Genentech, South San Francisco, CA) versus bevacizumab (IVB) (Avastin; Genentech, South San Francisco, CA) for treatment of macular edema (ME) secondary to retinal vein occlusion (RVO) in routine clinical practice. PATIENTS AND METHODS: A retrospective study identified treatment-naïve patients with ME secondary to RVO where treatment with either IVB or IVR was initiated...
June 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28613220/optical-coherence-tomography-baseline-predictors-for-initial-best-corrected-visual-acuity-response-to-intravitreal-anti-vascular-endothelial-growth-factor-treatment-in-eyes-with-diabetic-macular-edema-the-chartres-study
#3
Ana R Santos, Miguel  Costa, Christian Schwartz, Dalila Alves, João Figueira, Rufino Silva, Jose G Cunha-Vaz
PURPOSE: To identify baseline optical coherence tomography morphologic characteristics predicting the visual response to anti-vascular endothelial growth factor therapy in diabetic macular edema. METHODS: Sixty-seven patients with diabetic macular edema completed a prospective, observational study (NCT01947881-CHARTRES). All patients received monthly intravitreal injections of Lucentis for 3 months followed by PRN treatment and underwent best-corrected visual acuity measurements and spectral domain optical coherence tomography at Baseline, Months 1, 2, 3, and 6...
May 2, 2017: Retina
https://www.readbyqxmd.com/read/28499055/sequential-sterile-intraocular-inflammation-associated-with-consecutive-intravitreal-injections-of-aflibercept-and-ranibizumab
#4
Dilraj S Grewal, Tayler Schwartz, Sharon Fekrat
The authors report the unique response of two patients treated for cystoid macular edema (CME) secondary to central retinal vein occlusion (CRVO) who developed sequential episodes of likely sterile inflammatory responses following separate intravitreal injections of aflibercept (Eylea; Regeneron, Tarrytown, NY) and ranibizumab (Lucentis; Genentech, South San Francisco, CA) despite multiple previous uneventful injections for CME secondary to CRVO. Following the twenty-fifth aflibercept and seventh ranibizumab injection, two patients developed an acute inflammatory response, which was treated empirically with intravitreal antibiotics and topical and oral steroids (in Case 2)...
May 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28498374/ranibizumab-pretreatment-in-diabetic-vitrectomy-a-pilot-randomised-controlled-trial-the-radivit-study
#5
O Comyn, L Wickham, D G Charteris, P M Sullivan, E Ezra, Z Gregor, G W Aylward, L da Cruz, D Fabinyi, T Peto, M Restori, W Xing, C Bunce, P G Hykin, J W Bainbridge
PurposeOur aim was to evaluate the impact of intravitreal ranibizumab pretreatment on the outcome of vitrectomy surgery for advanced proliferative diabetic retinopathy. The objective was to determine the feasibility of a subsequent definitive trial and estimate the effect size and variability of the outcome measure.Patients and methodsWe performed a pilot randomised double-masked single-centre clinical trial in 30 participants with tractional retinal detachment associated with proliferative diabetic retinopathy...
May 12, 2017: Eye
https://www.readbyqxmd.com/read/28482126/cytosolic-expression-of-functional-fab-fragments-in-e-coli-using-a-novel-combination-of-dual-sumo-expression-cassette-and-enbase-%C3%A2-cultivation-mode
#6
Faegheh Rezaie, Fatemeh Davami, Kamran Mansouri, Sulmaz Agha Amiri, Ramin Fazel, Reza Mahdian, Noushin Davoudi, Somayeh Enayati, Mohammad Azizi, Vahid Khalaj
AIMS: The E. coli expression system is highly effective in producing recombinant proteins. However, there are some limitations in this system, especially in obtaining correctly folded forms of some complex proteins such as Fab fragments. To improve the solubility and folding quality of Fab fragments, we have examined the effect of simultaneous application of a SUMO fusion tag, EnBase(®) cultivation mode and a redox mutant strain in the E. coli expression system. METHODS AND RESULTS: A bicistronic gene construct was designed to express an anti-VEGF Fab fragment as a model system...
May 8, 2017: Journal of Applied Microbiology
https://www.readbyqxmd.com/read/28458510/evaluation-of-contrast-sensitivity-and-other-visual-function-outcomes-in-neovascular-age-related-macular-degeneration-patients-after-treatment-switch-to-aflibercept-from-ranibizumab
#7
Donald R Nixon, Nicholas Ap Flinn
PURPOSE: This study evaluated visual function and anatomic and vision-related quality-of-life outcomes in recalcitrant neovascular age-related macular degeneration (AMD) subjects switched to aflibercept (Eylea(®)) from ranibizumab (Lucentis(®)). METHODS: In a single-center study conducted in Barrie, ON, 40 patients with persistent fluid despite previous ranibizumab treatment were switched to aflibercept with 3 consecutive monthly doses. Main outcome measure was mean change from baseline to week 12 in Pelli-Robson contrast sensitivity (CS)...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28442372/long-term-release-and-stability-of-pharmaceutical-proteins-delivered-from-solid-lipid-implants
#8
Moritz Vollrath, Julia Engert, Gerhard Winter
Solid lipid implants (SLIs) prepared by twin-screw (tsc) extrusion represent a promising technology platform for the sustained release of pharmaceutical proteins. In this work, we report on two aspects, long-term release and stability of released protein. First, SLIs were produced by tsc-extrusion containing the low melting triglyceride H12 and the high melting triglyceride Dynasan D118. Two different proteins available in a freeze-dried matrix containing hydroxypropyl-β-cyclodextrine (HP-β-CD) were incorporated into the lipid matrix: a monoclonal antibody (mAb) from the IgG1 class and the fab-fragment Ranibizumab (Lucentis(®))...
April 22, 2017: European Journal of Pharmaceutics and Biopharmaceutics
https://www.readbyqxmd.com/read/28435212/testing-the-clinical-value-of-multifocal-electroretinography-and-microperimetry-and-the-effects-of-intravitreal-therapy-with-ranibizumab-on-macular-function-in-the-course-of-wet-age-related-macular-degeneration-a-1-year-prospective-study
#9
Mihaela Reinsberg, Ralf-Dieter Hilgers, Inger Lüdeke, Khaled Nassar, Swaantje Grisanti, Salvatore Grisanti, Julia Lüke, Matthias Lüke
PURPOSE: To investigate the clinical value of multifocal electroretinography (mfERG) and microperimetry and the effects of intravitreal therapy with ranibizumab (Lucentis(®)) on macular function in the course of neovascular age-related macular degeneration (nAMD). MATERIALS AND METHODS: We conducted a prospective single-arm interventional cohort study with 20 nAMD patients older than 50 years. Examinations were scheduled monthly for 1 year during intravitreal therapy with ranibizumab...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28419398/pre-existing-rpe-atrophy-and-defects-in-the-external-limiting-membrane-predict-early-poor-visual-response-to-ranibizumab-in-neovascular-age-related-macular-degeneration
#10
RANDOMIZED CONTROLLED TRIAL
Souska Zandi, Florian Weisskopf, Justus G Garweg, Isabel B Pfister, Christian Pruente, Florian Sutter, Katja Hatz
BACKGROUND AND OBJECTIVES: The aim of this study was to identify the rate of early visual acuity poor responders in patients with neovascular age-related macular degeneration (AMD) after the first intravitreal injection of ranibizumab (Lucentis; Genentech, South San Francisco, CA) and to determine potential predictors for early response. PATIENTS AND METHODS: Patients with choroidal neovascularization secondary to AMD were evaluated before and 1 month after their first ranibizumab treatment...
April 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28405488/multiple-intravitreal-ranibizumab-injections-for-persistant-choroidal-neovascularization-associated-with-presumed-ocular-histoplasmosis-syndrome
#11
Turgut Yılmaz, Seyhan Dikci, Oğuzhan Genç, Kayhan Mutlu
Presumed ocular histoplasmosis syndrome (POHS) is a clinical entity that is characterized by small, round, discrete, macular or mid peripheral atrophic (punched out) chorioretinal lesions (histo spots), peripapillary scarring, choroidal neovascularization (CNV), and the absence of anterior uveitis and vitritis. Diagnosis of this disorder is based upon characteristic clinical findings and a positive histoplasmin skin test or residence in an endemic region for Histoplasma capsulatum. There is no active systemic disease during diagnosis of POHS...
April 2017: Turkish Journal of Ophthalmology
https://www.readbyqxmd.com/read/28399772/nurse-led-ranibizumab-intravitreal-injections-in-wet-age-related-macular-degeneration-a-literature-review
#12
Emma Gregg
Aim The aim of this literature review was to explore the development of the role of specialist ophthalmic nurses in delivering ranibizumab intravitreal injections to patients with wet age-related macular degeneration (AMD), and to evaluate their contribution to reducing capacity pressures in medical retina services, while maintaining safe and effective standards of care. Method A systematic literature search was undertaken to identify relevant articles published between January 2000 and June 2015. A search of electronic databases was undertaken, and selected relevant journals were searched manually...
April 12, 2017: Nursing Standard
https://www.readbyqxmd.com/read/28388077/h-aggregates-granting-crystallization-induced-emissive-behavior-and-ultralong-phosphorescence-from-a-pure-organic-molecule
#13
Elena Lucenti, Alessandra Forni, Chiara Botta, Lucia Carlucci, Clelia Giannini, Daniele Marinotto, Andrea Previtali, Stefania Righetto, Elena Cariati
Solid-state luminescent materials with long lifetimes are the subject of ever-growing interest from both a scientific and a technological point of view. However, when dealing with organic compounds, the achievement of highly efficient materials is limited by aggregation-caused quenching (ACQ) phenomena on one side and by ultrafast deactivation of the excited states on the other. Here, we report on a simple organic molecule, namely, cyclic triimidazole (C9H6N6), 1, showing crystallization-induced emissive (CIE) behavior and, in particular, ultralong phosphorescence due to strong coupling in H-aggregated molecules...
April 20, 2017: Journal of Physical Chemistry Letters
https://www.readbyqxmd.com/read/28334720/intravitreal-dexamethasone-implant-versus-intravitreal-ranibizumab-for-the-treatment-of-macular-edema-secondary-to-retinal-vein-occlusion-in-a-chinese-population
#14
Xiaoya Gu, Xiaobing Yu, Shuang Song, Hong Dai
BACKGROUND: The aim of this work was to compare the efficacy of intravitreal dexamethasone implant (Ozurdex) and intravitreal ranibizumab (Lucentis) in the treatment of macular edema (ME) caused by retinal vein occlusion (RVO). METHODS: Thirty-two ME cases treated with Ozurdex and 32 ME cases treated with ranibizumab were enrolled, with 26 central (C)RVO and 6 branch (B)RVO subjects in each group. We compared the results of best-corrected visual acuity (BCVA), central retinal thickness, number of injections, and intraocular pressure (IOP) at 1, 2, 3, and 6 months after injection...
2017: Ophthalmic Research
https://www.readbyqxmd.com/read/28297035/short-term-effects-of-early-switching-to-ranibizumab-or-aflibercept-in-diabetic-macular-edema-cases-with-non-response-to-bevacizumab
#15
Mohammed Ashraf, Ahmed A R Souka, Hassan ElKayal
BACKGROUND AND OBJECTIVES: To study the effect of early switching to ranibizumab (Lucentis; Genentech, South San Francisco, CA) or aflibercept (Eylea; Regeneron, Tarrytown, NY) in cases of diabetic macular edema (DME) that have shown no response to bevacizumab (Avastin; Genentech, South San Francisco, CA). PATIENTS AND METHODS: A retrospective study involving 59 eyes of 45 patients with DME previously treated with bevacizumab. Patients were switched either to ranibizumab or aflibercept...
March 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28240411/in-situ-electroluminescence-color-tuning-by-thermal-deprotonation-suitable-for-thermal-sensors-and-anti-fraud-labels
#16
Umberto Giovanella, Elena Cariati, Elena Lucenti, Mariacecilia Pasini, Francesco Galeotti, Chiara Botta
A novel and versatile approach to tune photoluminescence and electroluminescence by in situ controlled thermal deprotonation is presented. This methodology, based on a single organic π-conjugated material (pyrene derivative), allows the manufacturing of Organic Light-Emitting Diodes (OLEDs) prototypes by solution methods with controlled tunable emission ranging from the orange (protonated form of the dye) to the blue (pristine or deprotonated form). While several protonation/deprotonation cycles can be performed on thin films, for the devices only one cycle is possible so that their use as anti-fraud labels can be envisaged...
February 27, 2017: Chemphyschem: a European Journal of Chemical Physics and Physical Chemistry
https://www.readbyqxmd.com/read/28138211/incidence-of-intraocular-pressure-elevation-following-intravitreal-ranibizumab-lucentis-for-age-related-macular-degeneration
#17
Gustavo Msm Reis, John Grigg, Brian Chua, Anne Lee, Ridia Lim, Ralph Higgins, Alessandra Martins, Ivan Goldberg, Colin I Clement
AIM: The aim of this article is to evaluate the rate of patients developing sustained elevated intraocular pressure (IOP) after ranibizumab (Lucentis) intravitreal (IVT) injections. DESIGN: This is a retrospective study. PARTICIPANTS: Charts of 192 consecutive patients receiving Lucentis for age-related macular degeneration (AMD) were retrospectively reviewed. MATERIALS AND METHODS: We enrolled patients with at least two IOP measurements between injections...
January 2017: Journal of Current Glaucoma Practice
https://www.readbyqxmd.com/read/28105123/effect-of-anti-vegf-drugs-combined-with-photodynamic-therapy-in-the-treatment-of-age-related-macular-degeneration
#18
Yi Dong, Guangming Wan, Panshi Yan, Yue Chen, Wenzhan Wang, Guanghua Peng
We analyzed the effects of anti-vascular endothelial growth factor (VEGF) drugs combined with photodynamic therapy (PDT) in the treatment of age-related macular degeneration (AMD). Ninety-six cases (192 eyes) of AMD were included in this study and randomly divided into the observation group and control group (n=48 cases per group). The control group was administered the treatment of Lucentis intravitreal injection alone and the observation group was administered Lucentis combined with PDT. The therapeutic effects were compared...
December 2016: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/28088881/an-industry-update-the-latest-developments-in-therapeutic-delivery
#19
Iain Simpson
This Industry Update covers the period from 1 October through to 31 October 2016, and is based on information sourced from company press releases, scientific literature, patents and various news websites. The month saw several news items covering drug-delivery devices, including a new sensor to monitor and support the use of inhalers; launch in the UK of a new autoinjector for Cimzia(®), UCB's rheumatoid arthritis drug; and approval of Roche's Lucentis(®) in a prefilled syringe. Research was also published to show the value of continuous blood pressure monitoring in dementia management...
February 2017: Therapeutic Delivery
https://www.readbyqxmd.com/read/28060398/incomplete-retinal-vascularization-after-ranibizumab-treatment-of-retinopathy-of-prematurity
#20
Shelley Day, Annis M Rainey, Clio A Harper
A former 24-week-old premature infant was treated with intravitreal ranibizumab (Lucentis; Genentech, South San Francisco, CA) in one eye and conventional laser in the other eye for aggressive posterior retinopathy of prematurity in both eyes. Fluorescein angiography performed at 149 weeks of age showed persistent avascularity of the temporal peripheral retina in the ranibizumab-treated eye. This case report confirms the need for long-term follow-up of patients treated with ranibizumab monotherapy. [Ophthalmic Surg Lasers Imaging Retina...
January 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
keyword
keyword
1765
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"